다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The American journal of the medical sciences, v.321 no.2, 2001년, pp.145 - 151
Arguedas, Miguel R. , Fallon, Michael B.
AI-Helper
Prevention has become an important component of medical therapy for a variety of diseases. Preventive strategies in liver disease are relatively underdeveloped and have focused mainly on specific complications of chronic liver disease and vaccination for viral hepatitis. Although public health initi...
Clin Liver Dis Zimmerman 4 73 2000 10.1016/S1089-3261(05)70097-0 Drug-induced liver disease
Hepatology Zimmerman 22 767 1995 10.1002/hep.1840220312 Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol. Analysis of instances of therapeutic misadventure
J Hepatol Larrey 26 suppl 47 1997 10.1016/S0168-8278(97)82333-1 Hepatotoxicity of herbal remedies
Clin Liver Dis Schiano 2 607 1998 10.1016/S1089-3261(05)70029-5 Liver injury from herbs and other botanicals
Gastroenterology Matteoni 116 1413 1999 10.1016/S0016-5085(99)70506-8 Nonalcoholic liver disease: A spectrum of clinical and pathological severity
J Hepatol Ueno 27 103 1997 10.1016/S0168-8278(97)80287-5 Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
MMWR Morb Mortal Wkly Rep 45 1 1996 Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices [published erratum appears in MMWR Morb Mortal Wkly Rep 1997;46:588]
J Infect Dis Koff 171 supp S19 1995 10.1093/infdis/171.Supplement_1.S19 Seroepidemiology of hepatitis A in the United States
MMWR Morb Mortal Wkly Rep 48 33 1999 Update: recommendations to prevent hepatitis B virus transmission-United States
Am J Kidney Dis Peces 29 239 1997 10.1016/S0272-6386(97)90036-6 Prospective analysis of the factors influencing the antibody response to Hepatitis B vaccine
Arch Int Med Allen 155 1726 1995 10.1001/archinte.1995.00430160044005 Self-report screening tests for alcohol problems in primary care
MMWR Morb Mortal Wkly Rep 47 1 1998 Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention
Can J Public Health Romanowski 85 205 1994 Sero-epidemiologic study to determine the prevalence and risk of hepatitis B in a Canadian heterosexual sexually transmitted disease population
N Engl J Med Edwards 328 1616 1993 10.1056/NEJM199306033282208 Screening for hemochromatosis
Can J Public Health Yuan 85 338 1994 Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men
Gastroenterology Balan 107 453 1994 10.1016/0016-5085(94)90171-6 Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients
Gastroenterology McLaren 114 543 1998 10.1016/S0016-5085(98)70538-4 Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis
Drug Saf Westphal 17 1 47 1997 10.2165/00002018-199717010-00004 Drug administration in chronic liver disease
Clin Pharmacol Ther Benson 35 831 1984 Evaluation of the safety of acetaminophen in chronic liver disease
Hepatology Schiff 26 Suppl 1 39S 1997 10.1002/hep.510260707 Hepatitis C, and alcohol
Hepatology Fong 13 64 1991 10.1002/hep.1840140111 The significance of antibody to hepatitis C virus in patients with chronic hepatitis B
N Engl J Med Vento 338 286 1998 10.1056/NEJM199801293380503 Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
Hepatology Keeffe 27 881 1998 10.1002/hep.510270336 Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
Am J Gastroenterol Dumot 94 1601 1999 10.1111/j.1572-0241.1999.01150.x Immunogenicity of hepatitis A vaccine in decompensated liver disease
Liver Transpl Surg Chalasani 4 128 1998 10.1002/lt.500040208 Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?
Hepatology Durand 26 219A 1997 Vaccination against hepatitis B virus in patients with chronic hepatitis C: efficacy, tolerance and response predictive factors in a case control study [abstract]
Ann Pharmacother Wintermeyer 29 299 1995 10.1177/106002809502900312 Rimantidine: a clinical perspective
Ann Intern Med Pagliaro 117 59 1992 10.7326/0003-4819-117-1-59 Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of non-surgical treatment
Hepatology D’Amico 22 332 1995 The treatment of portal hypertension: a meta-analytical review
Clinics in liver disease Grace 1 59 1997 10.1016/S1089-3261(05)70255-5 Pharmacologic therapy of portal hypertension and variceal hemorrhage
Gastroenterology Angelico 113 1632 1997 10.1053/gast.1997.v113.pm9352866 Effect of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis
Hepatology Groszmann 24 739 1996 10.1002/hep.510240345 Hepatic venous pressure gradient: Has the time arrived for its application in clinical practice?
Hepatology Lay 25 1346 1997 10.1002/hep.510250608 Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices
Hepatology Runyon 27 262 1998 10.1002/hep.510270139 Management of adult patients with ascites caused by cirrhosis
Hepatology Bernard 29 1655 1999 10.1002/hep.510290608 Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis
Hepatology Collier 27 273 1998 10.1002/hep.510270140 Screening for hepatocellular carcinoma
Med Clin North Am Khakoo 1121 1996 10.1016/S0025-7125(05)70482-X Etiology, screening and treatment of hepatocellular carcinoma
Hepato Gastroenterology Unoura 40 305 1993 High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.